Global Wearable Injectors Market - Forecasts from 2024 to 2029

The global wearable injectors market is projected to witness a CAGR of 20.67% during the forecast period to reach a total market size of US$25.141 billion by 2029, increasing from US$6.752 billion in 2022.

Wearable injectors are medical devices used for drug delivery systems. It is attached to the patient to deliver the drugs in a controlled manner. For the same reason, the devices are also called patch pumps or patch injectors. These devices are typically used for high-volume medications, drugs with high viscosities, and medicines that are required at regular intervals over a long period. The device reduces the need for multiple painful injections, making it convenient and user-friendly.

Wearable injectors are easy to use, especially when regular intervals of medication are required, thus providing a significant advantage over manual injections. The growing prevalence of chronic diseases and changing lifestyles around the globe are considered the key drivers for the global wearable injector market growth.

The wearable injectors are user-friendly, making them easy to self-administer. They also do not interfere with the user's day-to-day life. These devices improve dose accuracy and prevent needlestick injuries. Furthermore, rising healthcare costs and changes in technology have come up with innovative solutions that are efficient for managing the disease and also reduce the number of trips to hospitals and clinics to receive medical support for an injection.

Market Drivers:

• Increasing number of chronic diseases and lifestyle changes is anticipated in the market growth.

Chronic or non-communicable diseases like cancer, hypertension, diabetes, cardiovascular diseases, etc., are the leading causes of death globally. According to the World Health Organisation (WHO), 71% of all deaths are due to non-communicable diseases (NCDs). Globally, 17.9 million people are diseased due to cardiovascular disease annually. This is followed by cancer, respiratory diseases, and diabetes, accounting for 9.3 million, 4.1 million, and 1.5 million deaths, respectively.

Wearable injectors play an important role in managing non-communicable diseases like cardiovascular disease, cancer, diabetes, and autoimmune disease, amongst other diseases. In particular, with the growing sedentary lifestyle. These injectors are highly used devices to deliver drugs prescribed by the doctor at regular intervals. This eliminates the possibility of the drug being over- or under-dosed. Not only is it user-friendly, but it also saves time and money by reducing the number of trips to hospitals for medical assistance for injections.

• Technological advancement and increasing awareness are anticipated in the market growth.

With the increase in awareness of health, precautionary measures, and increased research and development in the medical industry, solutions like wearable injectors play an important role in assisting with various non-communicable diseases. As individuals are becoming more health-conscious, they are not just becoming aware of diseases but of all the alternative treatments and medical devices that are available for the management of such diseases.

Wearable infusion pumps are lightweight, compact devices that patients wear on their belts with an attached cannula on their skin. These off-body injectors are ideal for patients requiring continuous or intermittent infusions over an extended period, allowing them to move freely during treatment. Most insulin pumps are wearable on the belt, connected to the infusion set in subcutaneous fatty tissue.

Several steps are taken by governments and international organizations to raise awareness amongst the citizens to ensure timely assistance is provided. Further, with technological advancement, the manufacturing cost has been reduced significantly. By using highly advanced automation, companies can reach economies of scale. Increasing profits and focusing more on R&D for better solutions are also priorities.

Market Restraints:

• Environmental concerns could hamper the market growth.

Though wearable injectors are life-saving devices, they come at a cost to the environment. These devices are made of plastic bodies and are manufactured for one-time use purposes. Mishandling of devices and their improper disposal can also be hazardous. Since these devices need proper disposal and not all countries have a good disposal system, this not only affects other humans but also the ecosystem as plastic takes a long time to decompose.

Key Developments:

• May 2023 - Viridian Therapeutics partnered with Enable Injections, a global healthcare innovation company, to develop and manufacture the enFuse(R) wearable drug delivery system. The partnership aims to improve patient experience by allowing discreet medication administration at home or in clinics. The hidden needle and hands-free delivery system offer increased flexibility and convenience. Enable Injections focuses on improving the patient experience through drug delivery systems, while Viridian Therapeutics focuses on developing best-in-class medicines for patients with serious and rare diseases.
• May 2023- Ypsomed is enhancing self-injection device platforms with integrated human factors services to address the challenges of combination drug product development and regulatory approval. The company introduced end-to-end human factors services to its pharmaceutical partners, reshaping device turn-key HF services. This comprehensive service approach de-risks regulatory approval and expedites time-to-market for partners. Ypsomed has entered into a strategic partnership with Interface Analysis Associates LLC, a leading HF service provider with expertise in supporting the pharmaceutical industry. This move reinforces Ypsomed's position as a leading developer and manufacturer of self-injection solutions.
• February 2023- Insulet Corporation acquired the assets of Automated Glucose Control LLC (AGC), a Palo Alto-based company specializing in developing and commercializing automated insulin delivery technology. Insulet is a global leader in tubeless insulin pump technology, known for its Omnipod(R) brand of products. The Omnipod Insulin Management System offers a wearable design for up to three days of non-stop insulin delivery without the need to see or handle a needle. The Omnipod(R) 5 Automated Insulin Delivery System is a tubeless system integrated with a continuous glucose monitor for blood sugar management.
• June 2022- BD and Frazier Healthcare Partners agreed to acquire Parata Systems, a pharmacy automation solutions provider, for $1.525 billion. Parata's portfolio of solutions enables pharmacists to focus on higher-value clinical work and patient interactions, improving medication adherence, safety, and patient outcomes. The acquisition complements BD's medication management solutions across the care continuum, including acute care health systems, retail pharmacies, long-term care, and home settings. The deal aims to reduce costs, enhance patient safety, and improve the patient experience. The transaction complement BD's existing medication management solutions.

Segmentation:

By Type

• On-Body Injectors
• Off-Body Injectors

By Technology

• Motor-driven
• Expanding Battery
• Spring-based
• Rotary Pump
• Others

By Application

• Oncology
• Diabetes
• Cardiovascular Disease
• Autoimmune Disease
• Others

By End-User

• Hospitals and Clinics
• Ambulatory Surgery Centres
• Home Care Centres
• Other

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• UK
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others